NCT00208234

Effect of Xolair on Airway Hyperresponsiveness

The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 22 (estimated)
• Sponsor: Creighton University · Academic / Other
• Sex: All
• Age: 19 Years – 50 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine if Xolair can reduce the abnormal increase in limitation to airflow in patients with asthma in a relatively short time period. Another purpose is to determine if Xolair will decrease the amount of inflammation in the lungs of an asthmatic patient in the same time period.

Detailed description

Xolair, a recombinant humanized monoclonal anti-IgE antibody, has been studied extensively and proven efficacious in the treatment of asthma and other allergic disorders. In moderate to severe allergic asthmatic patients, Xolair reduced asthma exacerbations and improved symptoms. However, there is limited data on the effects of Xolair on airway hyperreactivity, an important component of asthma.

Conditions

• Allergic Asthma

Interventions

Type	Name	Description
DRUG	Omalizumab	0.016 mg/kg IgE
DRUG	Placebo for Omalizumab	Placebo
DRUG	omalizumab	Monoclonal antibody against IgE. 0.016 mg/kg IgE

Timeline

• Start date: 2004-01-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2005-09-21
• Last updated: 2011-09-23

Locations

1 site across 1 country: United States